Irbesartan: profile and news

Sanofi expects Acomplia launch in 06; profits up  Feb 24, 2006
...and Lovenox (enoxaparin), while other big sellers such as the cancer drugs Taxotere (docetaxel) and Eloxatin (oxaliplatin) and Avapro (irbesartan) for high ... - Pharma Times (subscription),

Do Lackluster Trial Findings Mean New Avenues Are Needed for Heart ...  Feb 9, 2006
The finding that an anticoagulation regimen of clopidogrel and irbesartan for the prevention of vascular events was inferior to using warfarin, the standard ... - Journal of American Medical Association (subscription),

Novartis New Phase III Data With SPP100 (aliskiren, Rasilez) ...  Jan 19, 2006
...efficacy of SPP100 in co-administration with the ACE-inhibitor (ramipril), the diuretic (hydrochlorothiazide - HCTZ) and the ARB (irbesartan), in hypertensive ... - Biotech Intelligence (press release),

Addition of Aliskiren to Irbesartan Improves Blood Pressure ...  Nov 15, 2005
DALLAS, TX -- November 15, 2005 -- Renin inhibition with aliskiren in combination with irbesartan appears to provide increased suppression of the renin ... - DG News

Aliskiren, the First Effective Oral Renin Inhibitor, Provides ...  Nov 15, 2005
...significantly greater night-time ambulatory BP measurement reductions (ABPM; continuous blood pressure monitoring) when added to irbesartan, an angiotensin ... - PR Newswire (press release),

Keryx Announces Positive Final Results from Phase 2 Clinical Study ...  Nov 11, 2005
The CSG trial of ACE Inhibition in Type 1 Diabetic Nephropathy and the recently completed trial of Irbesartan in Type 2 Diabetic Nephropathy (IDNT) led to FDA ... - PR Newswire (press release),

Sanofi-aventis Third Quarter 2005: Adjusted EPS(1) up 27.4%, Net ...  Nov 7, 2005
...in our consolidated net sales (with Bristol-Myers Squibb on Plavix(R)/ Iscover(R) (clopidogrel) and Aprovel(R)/Avapro(R)/Karvea(R) (irbesartan) and with ... - PR Newswire (press release),

ACTIVE-W trial discontinued, a clear benefit in favour of Warfarin  Sep 10, 2005
Study treatments for the ACTIVE W trial of the ACTIVE ( Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ) program have ... - Xagena.it,

Hypertension Drug Combination Yields High Rate of Blood Pressure ...  Sep 19, 2005
The remaining 736 people were given the combination pill of irbesartan (an angiotensin II receptor blocker) and a diuretic, hydrochlorothiazide, in ... - eMaxHealth.com,

Novartis Phase III Data With SPP100 (Aliskiren) Demonstrates ...  Sep 19, 2005
...efficacy of SPP100 in co-administration with the ACE-inhibitor (ramipril), the diuretic (hydrochlorothiazide - HCTZ) and the ARB (irbesartan), in hypertensive ... - Yahoo! News (press release)

Sanofi-Aventis ends key part of Plavix study for atrial ...  Sep 7, 2005
It will also continue the study of the group's Avapro (Irbesartan) high-blood pressure drug for AT treatment compared against a placebo. ... - Forbes

CV Therapeutics Announces Clinical Data on Perindopril From ASCOT ...  Aug 30, 2005
Other -- Effects of Irbesartan and Perindopril on Endothelial Function and Inflammatory Process in Patients with Stable Angina Pectoris: Evidence for Anti ... - PR Newswire (press release),

Drug duo treats stubborn high blood pressure  Aug 30, 2005
...unable to control their high blood pressure with a wide variety of single-drug treatments responded to a combination of high-dose irbesartan, a hypertension ... - Macleans,

Erythropoiesis-Stimulating Protein Therapy and the Decline of ...  Aug 12, 2005
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 ;345: 851- 60. ... - RedNova.com,

Clinical Management of the Metabolic Syndrome  Aug 1, 2005
Results from a subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions In Diverse Patient Populations (INCLUSIVE) trial were reported to determine ... - Medscape (subscription)

Strong net sales growth in the first half of 2005: 11.0% on a ...  Jul 19, 2005
...in our consolidated net sales (with Bristol-Myers Squibb on Plavix(R)/ Iscover(R) (clopidogrel) and Aprovel(R)/Avapro(R)/Karvea(R) (irbesartan) and with ... - Canada NewsWire (press release) <**results**>

Keryx Biopharmaceuticals, Inc. Initiates Pivotal Phase 3 and Phase ...  Jun 29, 2005
...converting enzyme (ACE) inhibition trial of captopril in Type 1 diabetic nephropathy and the angiotensin II receptor blocker (ARB) trial of irbesartan in Type ... - Yahoo News (press release)

Attention Health and Lifestyle Editors:  Jun 2, 2005
Inhibition of sympathetic outflow by the angiotensin II receptor anatagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to ... - Canada NewsWire (press release),

Hypertension drug combination yields high rate of blood pressure ...  May 18, 2005
The remaining 736 people were given the combination pill of irbesartan (an angiotensin II receptor blocker) and a diuretic, hydrochlorothiazide, in ... - News-Medical.net

Combo pill for hypertension  May 18, 2005
The research involving more than 700 people found that 18 weeks of treatment with the combination pill of irbesartan (an angiotensin II receptor blocker) and ... - Health24

ASH: Hard-to-Treat Hypertensive Patients Respond to Aggressive ...  May 19, 2005
...variety of anti-hypertensive agents achieved blood pressure goals on a high dose of 300 mg of the angiotensin-receptor blocker Avapro (irbesartan) paired with ... - MedPage Today

Sanofi-aventis 2005 First-Quarter Net Sales Growth Ahead of World ...  May 12, 2005
...in our consolidated net sales (with Bristol-Myers Squibb on Plavix(R)/Iscover(R) (clopidogrel) and Aprovel(R)/Avapro(R)/Karvea(R) (irbesartan) and with ... - PR Newswire

Keryx Biopharmaceuticals, Inc. Announces Data Presentation on KRX ...  Apr 28, 2005
The CSG conducted pivotal trials of ACE Inhibition in Type 1 Diabetic Nephropathy and of Irbesartan in Type 2 Diabetic Nephropathy (IDNT), both of which led to ... - PrimeZone

Improvement in Hypertensive Retinopathy after Treatment of ...  May 4, 2005
Ten months later, after treatment with a combination of irbesartan, atenolol, and amlodipine, the patient's blood pressure was 110/70 mm Hg. ... - New England Journal of Medicine (subscription),

Keryx Biopharmaceuticals, Inc. Announces Data Presentation on KRX ...  29 Apr 2005
The CSG conducted pivotal trials of ACE Inhibition in Type 1 Diabetic Nephropathy and of Irbesartan in Type 2 Diabetic Nephropathy (IDNT), both of which led to ... - PrimeZone

The "Hate-Love" Relationship With Blood Pressure  Apr 12, 2005
Another trial that is going on now is called Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE), and the National Institutes of Health ... - Medscape (subscription)

New Data Shows Telmisartan (Micardis/Pritor) Provides Effective ...  Apr 1, 2005
Lewis EJ, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. ... - PharmaLive.com,

Novartis investigational renin inhibitor Aliskiren offers once ...  Mar 11, 2005
...the antihypertensive agent Aliskiren vs. placebo and another antihypertensive, irbesartan. Aliskiren (SPP100) is potentially the ... - Medical News Today,

sanofi-aventis Reports Strong Growth of 18.2% in 2004 Adjusted(1) ...  Feb 28, 2005
...in our consolidated net sales (with Bristol-Myers Squibb on Plavix(R)/Iscover(R) (clopidogrel) and Aprovel(R)/Avapro(R)/Karvea(R) (irbesartan) and with ... - PR Newswire (press release)

Management of Hypertension in Older Persons  Feb 21, 2005
ARBs (ie, candesartan [Atacand], irbesartan [Avapro], losartan [Cozaar], valsartan [Diovan]) are reasonable alternatives for those with ACE inhibitor ... - RedNova.com,

No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.

In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine. However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible. Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isozymes 1A1, 1A2,2A6,2B6,2D6,2E1,or 3A4.

In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin. The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.